Genelux (GNLX) vs Spruce Biosciences (SPRB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Genelux (GNLX) has outperformed Spruce Biosciences (SPRB) over the past year, losing 57.7% versus a loss of 74.9%. Spruce Biosciences is the larger company by market cap ($114.0 million vs $109.5 million), about 1.0 times the size, while Genelux is growing revenue faster (+0.0% vs -100.0%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GNLX | SPRB |
|---|---|---|
| Share price | $2.42 | $39.65 |
| Market cap | $109.49M | $113.95M |
| 1-day change | -2.42% | -4.39% |
| YTD return | -44.50% | -54.48% |
| 1-year return | -57.69% | -74.88% |
| 5-year return | — | -99.84% |
| Forward P/E | — | 7.97 |
| EPS (TTM) | $-0.86 | $-39.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $8.00K | $0 |
| Revenue growth (YoY) | 0.00% | -100.00% |
| Net income (latest FY) | $-32.15M | $-38.97M |
| Operating margin | -415175.00% | — |
| Net margin | -401812.50% | — |
| 52-week high | $8.54 | $154.95 |
| 52-week low | $2.29 | $38.06 |
| Distance from 52-week high | -71.65% | -74.41% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +678.10% | +273.27% |
| Average volume | 288.93K | 78.11K |
| Shares outstanding | 45.25M | 2.87M |
| Employees | 25 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GNLX has outperformed SPRB by 17.2 percentage points over the past year.
- Genelux grew revenue faster in its latest fiscal year (0.00% vs -100.00%).
About Genelux
GNLX stock →Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
About Spruce Biosciences
SPRB stock →Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
GNLX vs SPRB FAQ
Which is bigger, Genelux or Spruce Biosciences?
Spruce Biosciences (SPRB) is larger, with a market capitalization of $113.95M compared with $109.49M for Genelux (GNLX).
Which stock has performed better over the past year, GNLX or SPRB?
GNLX returned -57.69% over the past 12 months, compared with -74.88% for SPRB (price return, excluding dividends). Past performance does not predict future results.
Are Genelux and Spruce Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.